Skip to content

Clinical trials

Withdrawn Myeloproliferative Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myeloproliferative Disorders Status: Withdrawn Clear all

27 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20061
20071
20083
20121
20142
20161
20171
20181
20203
20213
20221
20242
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Withdrawn27

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
M.D. Anderson Cancer Center3
Fred Hutchinson Cancer Center2
University of Medicine and Dentistry of New Jersey2
Alliance for Clinical Trials in Oncology1
Case Comprehensive Cancer Center1
City of Hope Medical Center1
Guizhou Bailing Group Pharmaceutical Co Ltd1
Leland Metheny1
Masonic Cancer Center, University of Minnesota1
Mayo Clinic1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myeloproliferative Disorders27
Primary Myelofibrosis16
Leukemia, Myeloid, Acute15
Precursor Cell Lymphoblastic Leukemia-Lymphoma15
Leukemia, Lymphocytic, Chronic, B-Cell14
Myelodysplastic Syndromes14
Leukemia, Myelomonocytic, Chronic13
Lymphoma, Non-Hodgkin13
Lymphoma, B-Cell, Marginal Zone12
Lymphoma, Follicular12

Trials

Showing 51 to 27 of 27. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.